FDA lifts partial clinical hold on Cell Therapeutics drug

The FDA has lifted a partial clinical hold on Cell Therapeutics' (CTIC +3.1%) Tosedostat blood cancer drug.

The agency placed the hold in June following the death of a patient in a trial in which the treatment was given along with chemotherapy.

Tosedostat is in Phase II trials in elderly patients with newly diagnosed and relapsed acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs